Document:

EXHIBIT 10.2

 

LICENSE AGREEMENT

 

This LICENSE AGREEMENT (“Agreement”) is entered into and made effective as of the 6th day of July, 2009 (“Effective Date”) by and between Nascent Biologics, Inc., a Delaware corporation (“Licensee”), and Hideaki Hagiwara and Hagiwara Institute of Health Integrated Medical Sciences Association Foundation, a 501(c)(3) non-profit corporation (“HIHIMSA Foundation” and, together with Hideaki Hagiwara, “Licensor”). Licensor and Licensee are referred to herein collectively as the “Parties” and each individually as a “Party”.

 

Background

 

A. Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

 

B. Licensee wishes to license, to Licensor, Licensee’s rights in such patents, information and materials on the terms and conditions set forth in this Agreement.

 

In consideration for the mutual covenants contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

1.  DEFINITIONS

 

“Affiliate” means any corporation, limited liability company, or other legal entity which directly or indirectly controls, is controlled by, or is under common control with Licensee. For the purpose of this Agreement, “control” means the direct or indirect ownership of at least 50 percent (50%) of the outstanding shares on a fully diluted basis or other voting rights of the subject entity to elect directors, or if not meeting the preceding, any entity owned or controlled by or owning or controlling at the maximum control or ownership right permitted in the country where such entity exists.

 

“Licensed Patents” means, collectively: (i) the patents listed in Exhibit A hereto; (ii) any and all divisionals, continuations, continued prosecution applications, continuations-in-part, substitutes, reissues, renewals, reexaminations and extensions of any or all such patents and patent applications; (iii) any and all foreign counterparts to any of the foregoing, including any and all utility models; (iv) any and all other patents and patent applications claiming priority to any of the patents and patent applications of (i), (ii) or (iii); (v) any and all other patents and patent applications from which any of the patents and patent applications of (i), (ii) or (iii) claim priority; and (vi) all rights of priority in and to any of the foregoing patents and patent applications.

 

	 
	
1

	

 

“Licensed Product” means a product or service the making, use, sale, offer to sell, or import of which in the applicable jurisdiction, where and when occurring would if conducted by a non-patent owner or licensee infringe upon a claim of an issued and unexpired Licensed Patent that (i) has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, where such decision is unappealable or unappealed within the time allowed for appeal; (ii) has not been rendered unenforceable through disclaimer or otherwise; and (iii) has not been lost through an interference, reexamination or reissue proceeding.

 

“Net Sales” means the payments received by Licensee or an Affiliate or a sublicensee of Licensee or an Affiliate from sales of Licensed Products. Sales made between any two or more of Licensee, Affiliates, or their sublicensees will not be counted in Net Sales. Net Sales will not include any Licensed Products used in clinical trials, used for research or other non-commercial uses, supplied as commercial samples or as charitable or humanitarian donations (whether supplied without charge or at a substantial discount). The calculation of Net Sales shall include only amounts specifically identifiable to a Licensed Product and amounts allocated to a Licensed Product, it being understood that amounts which are not specifically identifiable to a Licensed Product by virtue of their being identifiable to a group of products or products and services that includes a Licensed Product or to a combination product incorporating other active ingredients, or services shall be allocated thereto in a consistent and equitable manner that equitably reflects the contribution of the Licensed Product to such net sales. Amounts to be included in the calculation of Net Sales shall be those representing the gross amount received, less: (i) quantity and/or normal and customary cash discounts allowed or taken; (ii) credits, free goods, rebates, charge-backs, and/or adjustments by reason of rejections, returns, or retroactive price reductions, including without limitation those granted to managed care entities or pharmaceutical benefit management service entities; (iii) allowances for brokerage fees, freight, handling, and insurance; and (iv) sales and excise taxes, value-added taxes and their equivalents, duties, and any other governmental charges imposed upon the manufacture, importation, use or sale of Licensed Products.

 

“Related Materials” means the information and biological materials described in Exhibit A hereto.

 

2. LICENSE GRANT

 

2.1 License. Licensor hereby grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.

 

2.2 Sublicensees. Licensor agrees that it shall, upon reasonable request by Licensee, agree in writing with any sublicensee that such sublicensee's sublicense of the rights granted under this Agreement will survive any termination or expiration of this Agreement or any license granted hereunder to Licensee, whether as a direct grant from Licensor or otherwise; provided that the sublicensee is not in material breach of its obligations under such sublicense agreement, and that the sublicensee agrees that it will, in such circumstances, pay directly to Licensor the royalties on Net Sales that Licensor would have received under this Agreement with respect to such sublicense agreement, had this Agreement and the licenses hereunder continued to be in effect.

 

2.3 Delivery. Licensor shall deliver the Related Materials to Licensee within five (5) days following the execution of this Agreement.

 

	 
	
2

	

  

3. PAYMENT

 

3.1 License Fee. Licensee shall pay to Licensor a license fee of $2,000,000 payable in 6 payments of $300,000 per year commencing January 1, 2010 and one payment of $200,000 on January 1, 2016.

 

3.2 Royalties. Licensee shall pay to Licensor a royalty on Net Sales. The royalty rate shall be 2% on aggregate Net Sales of all Licensed Products from the Effective Date up to $10 million and the royalty rate shall be 1% on aggregate Net Sales of all Licensed Products from the Effective Date over $10 million. In the calculation of royalties, only one application of the percentage stated shall be made to the Net Sales of any Licensed Product, regardless of how many Licensed Patent rights, may be applicable thereto.

 

3.3 Payment. Royalties payable pursuant to this Agreement shall be due quarterly within sixty (60) days following the end of each calendar quarter in respect of Net Sales received in such quarter. Each such payment shall be accompanied by a statement of Net Sales for the quarter and the calculation of royalties payable hereunder. All monies due hereunder shall be paid in United States Dollars to Licensor. The rate of exchange to be used in converting foreign funds to United States Dollars shall be the actual rate at which Licensor, on the relevant date, purchases United States Dollars with such foreign funds.

 

3.4 Taxes. It will be Licensor’s obligation to pay all taxes due on the amounts that Licensor receives under this Agreement and Licensee may withhold from payments due Licensor under this Agreement, any taxes that it is required to withhold on such payments. Licensee will provide Licensor with receipts for any such taxes withheld and paid.

 

4. PATENT PROSECUTION AND ENFORCEMENT

 

4.1 Prosecution. As of the Effective Date, Licensee shall assume control, at Licensee’s expense, of the preparation, filing, prosecution and maintenance of all patents and patent applications which claim any of the Licensed Patents.

 

	 
	
3

	

 

4.2 Assistance. Licensor shall cooperate with Licensee, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary in the preparation, prosecution and maintenance of all applications and patents described in this Section 4. Licensor either has provided, or shall provide promptly after the Effective Date, to Licensee copies of the Licensed Patents and their prosecution histories (including pending applications and all office actions), and such other information with respect thereto as Licensee may reasonably request.

 

5. INFRINGEMENT

 

5.1 Each party shall promptly inform the other of any suspected infringement of any of the Licensed Patents or the infringement or misappropriation of Related Materials by a third party (“Covered Infringement”).

 

5.2 If the suspected infringement or misappropriation involves a Covered Infringement, Licensee shall, within 60 days of the first notice referred to in Section 5.1, inform Licensor whether or not Licensee intends to institute suit against such third party with respect to such Covered Infringement. Licensor will not take any steps toward instituting suit against any third party involving a Covered Infringement until Licensee has informed Licensor of its intention pursuant to the previous sentence.

 

5.3 If Licensee notifies Licensor that Licensee intends to institute suit against a third party with respect to a Covered Infringement, Licensee may bring such suit on its own and shall in such event bear all costs of, and shall exercise all control over, such suit. Licensee may, at its expense, bring such action in the name of Licensor and/or cause Licensor to be joined in the suit as a plaintiff. Recoveries, if any, whether by judgment, award, decree or settlement, shall after the reimbursement of Licensee for its costs in such action, be treated as if they were Net Sales for purposes of calculating royalties under Section 3.2.

 

5.4 If Licensee notifies Licensor that it does not intend to institute suit against such third party with respect to a Covered Infringement (or fails to give any notice in this respect or to actually bring a suit against the third party), Licensor may institute suit on his own. Licensor shall bear all costs of, and shall exercise all control over, such suit. Recoveries, if any, whether by judgment, award, decree or settlement, shall belong solely to Licensor.

 

6. CONFIDENTIALITY

 

In the course of performing the transactions contemplated by this Agreement, whether before or after the Effective Date, a Party may disclose, or may have disclosed, to the other confidential information belonging to the disclosing party (“Discloser’s Confidential Information”). The receiving party will maintain in confidence the Discloser’s Confidential Information and will not use it for any purpose except as authorized hereunder. Each Party shall safeguard such information against disclosure to third parties, including without limitation employees and persons working or consulting for such party that do not have an established, current need to know such information for purposes authorized under this Agreement. This obligation of confidentiality does not apply to restrict use or disclosure by the receiving party of information and material that meet one or more of the following criteria:

 

(a) they were properly in the possession of the receiving party, without any restriction on use or disclosure, prior to receipt from the other party;

 

	 
	
4

	

 

(b) they are at the time of disclosure hereunder in the public domain by public use, publication, or general knowledge;

 

(c) they become general or public knowledge through no fault of the receiving party following disclosure hereunder;

 

(d) they are properly obtained by the receiving party on a non-confidential basis from a third party not under a confidentiality obligation to the disclosing party hereto;

 

(e) they are independently developed by or on behalf of the receiving party without the assistance of the confidential information of the other party;

 

(f) they are required to be disclosed by order of any court or governmental authority; provided, however, that the receiving party shall use its best efforts to give the disclosing party prior notice of any such disclosure so as to afford the disclosing party a reasonable opportunity to seek, at the expense of the disclosing party, such protective orders or other relief as may be available in the circumstances.

 

Notwithstanding the foregoing provisions Licensee shall be permitted to disclose:

 

(a) any Licensor Confidential Information to regulatory authorities and to potential licensees or collaborators and other persons performing tests and studies, and as needed or useful for developmental, regulatory and/or marketing purposes, which disclosure shall be made so far as reasonably practicable under conditions of confidentiality and limited use; and

 

(b) any Licensor Confidential Information to its patent attorney or agent or any patent authority in any country as shall be reasonably required for filing or prosecuting any patent application with respect to any Licensed Product or any related process.

 

Neither Party shall make any public announcement or other publication regarding this Agreement (whether as to the existence or terms hereof) without the prior, written consent of the other party, which consent shall not be unreasonably withheld; provided that the foregoing shall not prohibit any disclosure that, in the opinion of counsel to the disclosing party, is otherwise required by any applicable law, regulation, or by any competent governmental authority.

 

	 
	
5

	

 

7. REPRESENTATIONS AND WARRANTIES

 

7.1 Licensor represents and warrants that Licensor exclusively owns all right, title and interest, including all intellectual property rights, in and to the Licensed Patents and Related Materials and has the full right and authority to grant the rights and licenses granted to Licensee herein. Licensor further represents and warrants that (i) there is no other or prior license or grant of rights, whether by Licensor, any inventor under the Licensed Patents, or any prior owner of the Licensed Patents, or otherwise, under any of Licensed Patents and/or the Related Materials; (ii) there is no pending or threatened interference, re-examination, opposition or other proceeding or challenge to or involving any of the Licensed Patents and (iii) there is no pending or threatened claim of infringement relating to the Licensed Patents or Related Materials or to any activities of Licensor thereunder, and to the knowledge of Licensor there is no basis for a claim of infringement of any third party patent or other proprietary right with respect to the Licensed Patents, Related Materials, or any such activities.

 

7.2 Each of Licensee and Licensor represents and warrants to the other that it has obtained, and will at all times during the term of this Agreement hold and comply with, all licenses, permits and authorizations necessary to perform this Agreement, as now or hereafter required under any applicable statutes, laws, ordinances, rules and regulations of the United States and any applicable foreign, state, and local governments and governmental entities.

 

8. TERM AND TERMINATION

 

8.1 Term. The term of this Agreement shall begin on the Effective Date and shall, unless earlier terminated as provided herein, continue until the expiration of the last remaining Licensed Patent. If the term of this Agreement is not so terminated prior to such expiration, any and all then-remaining licenses to Licensee hereunder shall, upon and after such expiration, become royalty-free, paid-up and irrevocable, as shall the licenses hereunder with respect to a Licensed Product in any nation following the expiration of the Licensed Patent for such Licensed Product in such nation.

 

8.2 Licensee Right to Terminate. Licensee may at its option terminate this Agreement, either in whole or as to one or more nations, upon at least 90 days’ prior written notice to Licensor.

 

8.3 Licensor Right to Terminate. If on the third anniversary of the Effective Date, Licensee shall not have on or prior to such date raised an aggregate of $5,000,000 in value through one or more investments in Licensee or its securities or convertible debt instruments, or collaboration-related funding obtained by Licensee, Licensor shall have the right to terminate the Agreement and all rights granted to Licensee under this Agreement.

 

	 
	
6

	

 

8.4 Termination for Breach. If either party materially breaches any of the terms, conditions or agreements contained in this Agreement to be kept, observed or performed by it, the other party may terminate this Agreement, at its option and without prejudice to any of its other legal or equitable rights or remedies, by giving the party who committed the breach 90 days’ prior written notice, unless the notified party within such 90-day period shall have cured the breach; provided, however, that if the party claimed to be in breach disputes in good faith that the claimed breach exists, such 90-day period will not start to run until such dispute has been resolved.

 

8.5 Survival. Licensee’s obligations regarding payment of royalties accrued as of the date of termination, and the provisions of Sections 6, 7, 8 and 9 hereof shall survive any expiration or termination of this Agreement. If this Agreement is terminated prior to January 1, 2016, Licensee’s obligation to make payments under Section 3.1 shall not continue following termination, unless the Agreement is terminated by Licensor under Section 8.4. In addition, in the event of any termination of this Agreement by either party in a situation in which Licensee will not obtain a continuing exclusive, royalty-free, paid-up and irrevocable license as described in Section 8.1, Licensee and its Affiliates and sublicensees will nevertheless be permitted, for a period of six (6) months following the effective termination date, to distribute and sell all Licensed Products that were in inventory on the effective termination date, in accordance with the terms of this Agreement.

 

9. MISCELLANEOUS

 

9.1 Governing Law. This Agreement and any claim arising under or relating to this Agreement shall be governed by the internal substantive laws of the State of California without regard to or application of choice of law rules or principles.

 

9.2 Jurisdiction. Each Party hereby agrees to jurisdiction and venue in the courts of the State of California and the Federal courts sitting in San Diego for all disputes and litigation arising under or relating to this Agreement.

 

9.3 Entire Agreement. The terms and conditions of this Agreement, including its exhibits, constitute the entire agreement between the Parties with respect to the subject matter hereof, and merge and supersede all prior and contemporaneous agreements, understandings, negotiations and discussions with respect to such subject matter, including the Letter of Intent entered into by the Parties on January 21, 2009. Neither of the Parties shall be bound by any conditions, definitions, warranties, understandings, or representations with respect to the subject matter hereof, other than as expressly provided herein. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. No oral explanation or oral information by either Party hereto shall alter the meaning or interpretation of this Agreement. No amendments or modifications shall be effective unless in a writing signed by authorized representatives of both Parties.

 

9.4 Counterparts. This Agreement may be executed in two (2) or more counterparts, all of which, taken together, shall be regarded as one and the same instrument.

 

	 
	
7

	

 

9.5 Notices: All notices required or permitted to be given hereunder shall be in writing, shall make reference to this Agreement, and shall be delivered by FedEx, by hand, or dispatched by facsimile, prepaid air courier or by registered or certified airmail, postage prepaid, addressed as follows:

 

	
If to Licensor:

	
 

	
If to Licensee:

	
 

	
 

	
 

	
Hideaki Hagiwara, Ph.D.

	
 

	
Nascent Biologics, Inc.

	
464 Propsect, PH-9

	
 

	
10246 Parkdale Avenue,

	
La Jolla, CA 92037

	
 

	
San Diego, CA 92126

	 		
Attn: President

 

Such notices shall be deemed served when received by addressee or, if delivery is not accomplished by reason of some fault of the addressee, when tendered for delivery. Either Party may give written notice of a change of address and, after notice of such change has been received, any notice or request shall thereafter be given to such Party at such changed address.

 

9.6 Relationship of Parties. The Parties hereto are independent contractors. Neither Party has any express or implied right or authority to assume or create any obligations on behalf of the other or to bind the other to any contract, agreement or undertaking with any third party. Nothing in this Agreement shall be construed to create a partnership, joint venture, employment or agency relationship between Licensor and Licensee.

 

9.7 Severability. The terms and conditions stated herein are declared to be severable. If any paragraph, provision, or clause in this Agreement shall be found or be held to be invalid or unenforceable in any jurisdiction in which this Agreement is being performed, the remainder of this Agreement shall be valid and enforceable and the Parties shall use good faith to negotiate a substitute, valid and enforceable provision which most nearly effects the Parties’ intent in entering into this Agreement.

 

9.8 Interpretive Principle. For the purpose of this Agreement, except as otherwise expressly provided or unless the context otherwise requires, the terms “include”, “includes”, and “including” shall be deemed followed by “without limitation”.

 

9.9 Waiver. Failure by either Party to enforce any term of this Agreement shall not be deemed a waiver of future enforcement of that or any other term in this Agreement.

 

9.10 Attorney’s Fees. The prevailing Party in any litigation related to this Agreement shall be entitled to recover from the other Party its reasonable attorneys fees and costs.

 

9.11 Assignment. Licensor may not transfer or assign this Agreement without the prior written consent of Licensee, which Licensee may grant or deny in its sole discretion, and any attempt to transfer or assign this Agreement absent such consent shall be null and void. Licensee shall have the right to assign this Agreement, without the consent of Licensor, in connection with a merger, consolidation or reorganization of Licensee, or in connection with the sale of all or substantially all of the assets of Licensee related to this Agreement.

 

	 
	
8

	

 

In witness whereof, the Parties have executed this License Agreement by their duly authorized representatives as of the Effective Date:

 

 

	LICENSOR		LICENSEE	
		 		 	
	HIHIMSA Foundation	 	 Nascent Biologics, Inc.	 
		 		 	
	By:	/s/ Hideaki Hagiwara	 	Mark C. Glassy	 
	 	Signature	 	Signature	 
	 	Hideaki Hagiwara, Ph.D., Chairman	 	Mark Glassy, President	 

 

	By	/s/ Hideaki Hagiwara	 
	 	Signature	 
	 	Hideaki Hagiwara, Ph.D.	 

 

	 
	
9

	

 

Exhibit A

 

Related Materials

 

	
·

	
Cell line for the human antibody Pritumumab, also known as, CLN-H11 and CLN IgG and the sister antibody to Pritumumab known as CLNH5 (the “Antibodies”)

	
 

	 
	
·

	
All data generated in the research and development of the Antibodies, including but not limited to clinical trial data

	
 

	 
	
·

	
Protein and DNA sequences of entire Antibodies

 

Licensed Patents

 

Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)

 

4,618,577 – human-human hybridoma, CLNH5

 

4,761,377 - human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

 

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

 

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

 

5,286,647 – human-human hybridomas for neoplasms

 

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

 

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

 

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

 

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

 

6,051,693 – CLNH11-specific antibodies

 

6,090,924 – human-human CLNH5-specific antibodies

 

6,165,467 – stabilized human monoclonal antibody preparation

 

	 
	
10

	

 

 

	 
	
11

	

 

 

	 
	
12

	

 

 

 13Exhibit 10.47

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 230.406

 

TRANSFER AGREEMENT

 

THIS TRANSFER AGREEMENT
(“Agreement”) is entered into as of October 8, 2014 (the “Effective Date”) between CAPRICOR THERAPEUTICS,
INC., a Delaware corporation with offices located at 8840 Wilshire Blvd., 2nd Floor, Beverly Hills, California 90211 (“Capricor”)
and MEDTRONIC, INC., a Minnesota corporation with offices at 710 Medtronic Parkway, Minneapolis, Minnesota 55432, U.S.A.
(“Medtronic”) (each a “Party,” collectively the “Parties”).

 

WITNESSETH:

 

WHEREAS, Medtronic is the
sole or co-exclusive owner (together with Capricor) of certain Patents and Applications for United States, foreign and international
Letters Patents identified in the attached Schedule A describing inter alia medical delivery systems and for various natriuretic
peptides for treating various medical conditions in patients (collectively, the “Natriuretic Peptide Patents”);

 

WHEREAS, Capricor is in
the business of developing therapies using Natriuretic peptides useful in treating certain medical conditions in human patients;

 

WHEREAS, Capricor desires
to acquire all rights, title and interest including but not limited to, legal title to the Natriuretic Peptide Patents held by
Medtronic; and

 

WHEREAS, Medtronic has
the power and authority to grant to Capricor such rights, title and interest to the extent they possess the same.

 

NOW, THEREFORE, in consideration
of the mutual promises and covenants herein contained, the Parties hereto agree as follows:

 

Article
1

DEFINITIONS

 

For purposes of this Agreement, the following
definitions shall apply:

 

		A.	“Affiliate” means, with respect to a Party or legal entity, any person that controls,
is controlled by, or is under common control with such Party or legal entity. For purposes of this definition, “control”
shall refer to (a) in the case of a person that is a corporate entity, direct or indirect ownership of fifty percent (50%) or more
of the stock or shares having the right to vote for the election of a majority of the directors of such person or (b) in all cases,
whether or not the person is a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction
of, the management or policies of such person, whether through the ownership of voting securities, by contract or otherwise.

 

    	 

    	 

    

 

		B.	“Change of Control” means the occurrence of any of the following: (i) any consolidation
or merger of a Party with or into any Third Party, or any other corporate reorganization involving a Third Party, in which those
persons or entities that are stockholders of such Party immediately prior to such consolidation, merger or reorganization own less
than fifty percent (50%) of the surviving entity’s voting power immediately after such consolidation, merger or reorganization;
(ii) a change in the legal or beneficial ownership of fifty percent (50%) or more of the voting securities of any Party (whether
in a single transaction or series of related transactions) where, immediately after giving effect to such change, the legal or
beneficial owner of more than fifty percent (50%) of the voting securities of such Party is a Third Party; or (iii) the sale, transfer,
or other disposition to a Third Party of all or substantially all of a Party’s assets in one or a series of related transactions.

 

		C.	“Intellectual Property” means all forms of intellectual property in any jurisdiction
and under any law, whether now or hereafter existing, including: (a) inventions, discoveries, patent applications, patents (including
letters patent, industrial designs, and inventor’s certificates), design registrations, invention disclosures, and applications
to register industrial designs, and any and all rights to any of the foregoing anywhere in the world, including any provisionals,
substitutions, extensions, supplementary patent certificates, reissues, re-exams, renewals, divisions, continuations, continuations
in part, continued prosecution applications, and other similar filings or notices provided for under the laws of the United States,
or of any other country or foreign jurisdiction; and (b) a license or the right to practice a claim in pending application for
Letters Patent or issued Letters Patent in the United States or a foreign jurisdiction.

 

		D.	“License” means any grant of a license by a licensor of any of the Natriuretic Peptide
Patents, including, but not limited to, field licenses, exclusive licenses, non-exclusive licenses, cross-licenses, covenants not
to sue, and any other license granted to practice or commercialize Product(s) under the Natriuretic Peptide Patents.

 

		E.	“Licensing Event” means a License, assignment or sale to a Non-Party of any of the
Natriuretic Peptide Patents. For purposes of clarity, a Change of Control of Capricor shall not constitute a sale or assignment
of the Natriuretic Peptide Patents, nor a Licensing Event.

 

		F.	“Licensing Revenue” means the value received by Capricor, whether in cash or in kind,
on account of a Licensing Event, including upfront, lump sum and similar payments received by Capricor, excluding payments received
(i) solely for the purchase of equity securities, (ii) as consideration for the sale of substantially all of Capricor’s assets,
(iii) as royalty payments made in connection with the sale of Products, (iv) as loans or in connection with the issuance of debt
instruments, (v) from third parties for costs related to general and administrative expenses, product and manufacturing development,
co-development activities, clinical trials, or research and development activities, or (vi) to be used for the costs of procuring
intellectual property rights from third parties which may be necessary for the development of Products. Notwithstanding the foregoing,
in the event that the Licensing Event involves either cross-licensing or a covenant not to sue, unless Capricor receives some monetary
consideration in connection therewith, there will be no payment due to Medtronic; however, in no circumstance shall any of the
events (i) through (vi) listed above, relieve Capricor, an Affiliate, or a Non-Party Licensee of the obligation to pay royalties
on Net Sales of Product.

 

    	2

    	 

    

 

		G.	“Natriuretic Peptide Patent(s)” means (i) any patent application listed in Schedule
A and any issued patent arising therefrom; (ii) any U.S. continuation, divisional and continuation-in-part patent application claiming
priority to any patent application listed in Schedule A, and any issued patent arising therefrom; (iii) any patent application
in any non-U.S. jurisdiction claiming priority to any patent application listed in Schedule A, and issued patent arising therefrom;
(iv) any patent application in any country claiming the benefit of any of the foregoing.

 

		H.	“Net Sales” means the gross amount of all revenues from any country (whether in the
form of cash or property) received from the sale of Products in an arms’ length transaction to a Non-Party by Capricor, or
a Non-Party Licensee as the case may be, excluding sales, use, value added, occupation or excise taxes, and other taxes based or
imposed based on the transfer of a Product(s) from one party to another or the provision of a service, excluding freight, duty
or insurance, and rebates, refunds, exchanges, discounts and allowances for credits for the foregoing and net of amounts written
off. Net Sales does not include the value received for a sale, License, or assignment of any Intellectual Property rights by Capricor,
or a Non-Party Licensee, which is handled separately as Licensing Revenue. Notwithstanding the foregoing, sales of Products to
hospitals or other institutions to be used in the conduct of clinical trials shall not be included in the calculation of Net Sales.
If the Product is sold as part of a larger bundle or kit that incorporates or includes other products in addition to the Product,
Net Sales will be computed using an average net selling price of the Product sold separately, or if such net selling price is unavailable,
it will be computed using that part of such sale as the Parties reasonably agree is allocated to the value of the Product as compared
to the value of the larger bundle or kit sold with the Product.

 

In the United States, Germany, France,
Italy, United Kingdom, China, Japan, Australia or Canada, if Capricor contracts with a Non-Party who is not a Non-Party Licensee
to sell or distribute the Products (e.g., a sale force, or a distributor), then Net Sales shall be calculated as if that Non-Party
was a Non-Party Licensee.

 

		I.	“Non-Party” means any party other than Medtronic or Capricor or their respective Affiliates.

 

		J.	“Non-Party Licensee” refers to a Non-Party that receives a License, or receives an
assignment of any Natriuretic Peptide Patent for use in conjunction with a Product.

 

		K.	“Product(s)” means any product(s) or systems that are sold, transferred, or otherwise
conveyed by Capricor or a Non-Party Licensee to a Non-Party for value, whether for cash or other consideration, the manufacture,
sale or use of which would infringe, or contribute to, or induce the infringement of, a Valid Claim.

 

    	3

    	 

    

  

		L.	“Royalty Payment” means a payment that is calculated based upon Net Sales. Any sale
of a Product by Capricor or a Non-Party Licensee, shall be subject to payment obligations to Medtronic specified in this Agreement.

 

		M.	“Valid Claim” means an issued claim of any unexpired patent included among the Natriuretic
Peptide Patents; and (i) which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental
body of competent jurisdiction which is unappealable or unappealed within the time allowed for appeal, (ii) which has not been
rendered unenforceable through disclaimer or otherwise, and (iii) which has not been lost through an interference proceeding or
abandoned.

 

		N.	Unless context clearly indicates otherwise, the singular of a term includes the plural, and the
plural of a term includes the singular.

 

Article
2

ASSIGNMENT

 

		A.	Medtronic hereby assigns to Capricor, upon and subject to all the terms and conditions of this
Agreement, all of its right, title and interest in and to all Natriuretic Peptide Patents.

 

		B.	The geographic territory of this Agreement shall be any country or jurisdiction where any application
for Letters Patent listed in Schedule A is pending or issued or wherein any application for Letters Patent claiming priority to
an application for Letters Patent listed in Schedule A is pending or issued.

 

		C.	With the foregoing assignment, Capricor receives all rights to the Natriuretic Peptide Patents,
including the right to grant Licenses and to make assignments without any approval from Medtronic, but the obligations in Article
4 remain nontransferable without Medtronic’s written approval.

 

		D.	Medtronic hereby assigns to Capricor all right and title Medtronic may have to actions for damages
due to infringement of the Natriuretic Peptide Patents prior to the Effective Date, including the right to bring actions to enforce
the Natriuretic Peptide Patents against any infringer of the Natriuretic Peptide Patents, and to retain any recovery from such
actions, subject only to the compensation requirements of Article 4.

 

Article
3

TERM/TERMINATION

 

		A.	This Agreement shall be effective as of the date of execution by the Parties and shall expire simultaneously
at the expiration of the last to expire of the Valid Claims (“Term”).

 

    	4

    	 

    

 

		B.	Capricor shall have the right to terminate this Agreement immediately in the event of a breach
of any covenant of Medtronic contained herein or upon thirty (30) days written notice to Medtronic in the event of a default by
Medtronic of any of its obligations hereunder which has not been cured within such 30-day period.

 

		C.	In addition to the termination provision contained in Section 4.G below, Medtronic shall have the
right to terminate this Agreement upon thirty (30) days written notice to Capricor in the event of a default by Capricor of any
of its obligations hereunder which has not been cured within such 30-day period.

 

		D.	In the event of a termination of this Agreement pursuant to the provisions contained herein, the
following shall apply:

 

		(i)	the Natriuretic Peptide Patents which were not owned or co-owned by Capricor prior to the Effective
Date of this Agreement shall be assigned back to Medtronic promptly after the effective date of the termination.

 

		(ii)	Capricor’s rights in and to the Natriuretic Peptide Patents that were co-owned by Capricor
pursuant to that certain Clinical Funding Agreement dated February 25, 2011 previously executed by Medtronic and Capricor (formerly
known as Nile Therapeutics, Inc.) (the “Clinical Funding Agreement”) shall remain with Capricor, subject to
the surviving terms and provisions thereof.

 

		(iii)	Capricor shall assign back to Medtronic those rights that were co-owned by Medtronic pursuant to
the Clinical Funding Agreement, subject to the surviving terms and provisions thereof.

 

Article
4

COMPENSATION

 

		A.	In consideration for the assignments granted under this Agreement, Capricor agrees to pay to Medtronic
the payments recited in paragraphs B through F in this Article, and in the manner recited in paragraphs G through K. Each of paragraphs
B through K below recite an independent payment obligation of Capricor to Medtronic and each of paragraphs B through K shall be
read independently.

 

		B.	Capricor or an Affiliate shall pay Medtronic [...***...] of any Licensing Revenue received
by Capricor on account of a Licensing Event during the term of this Agreement.

 

		C.	Capricor or an Affiliate shall pay Medtronic [...***...] of any monetary awards or settlements
received by Capricor as a result of enforcement of the Natriuretic Peptide Patents against a Non-Party entity, less the costs and
attorney’s fees incurred to enforce the Natriuretic Peptide Patents. The costs and attorney’s fees to enforce the Natriuretic
Peptide patents shall be subtracted from any awards or settlements prior to the [...***...] calculation.

 

*Confidential Treatment
Requested

    	5

    	 

    

 

		D.	Capricor or an Affiliate shall pay Medtronic [...***...] of Net Sales of Products.

 

		E.	Capricor or an Affiliate shall pay Medtronic one hundred thousand dollars ($100,000.00) within
seven (7) days after the mutual execution of this Agreement.

 

		F.	Capricor or an Affiliate shall make the following one-time payments to Medtronic within thirty
(30) days of the first achievement of each of the following development milestones by Capricor, or a Non-Party Licensee:

 

		(i)	$[...***...] upon enrollment of the first subject in a Phase III clinical trial of a
Product;

 

		(ii)	$[...***...] upon the first to occur of either (i) successful completion of a Phase III
clinical trial of a Product (i.e. upon meeting a primary clinical endpoint) or (ii) achieving regulatory approval in the United
States or a European Union country;

 

		(iii)	$[...***...] upon the first commercial sale of a Product in the United States; and

 

		(iv)	$[...***...] upon the first commercial sale of a Product in the European Union.

 

For the avoidance of doubt,
such milestones shall be paid once only and the total amount payable if all milestones are achieved is $7 million.

 

		G.	In order to show progress in the development pathway, either Capricor, an Affiliate or a Non-Party
Licensee will be required to commence a clinical trial of a CD-NP product within 18 months from the Effective Date of this Agreement
and if it fails to do so, Medtronic shall have the right to terminate this Agreement and have the rights to the Natriuretic Peptide
Patents reassigned to it by Capricor; provided, however, that in the event of any termination of this Agreement, any rights and
obligations which survived the expiration of then Clinical Funding Agreement will continue in full force and effect, including
the ownership of all intellectual property rights as set forth therein.

 

		H.	Royalty Payments owed Medtronic on sales by Capricor shall accrue on a semiannual calendar basis
(“Royalty Period”) and be payable no later than 90 (ninety) days after the termination of the preceding full semiannual
period, i.e., commencing on the first (1st) day of January and July, except that the first and last calendar periods may be “short,”
depending on the dates of the first and last commercial sale. Royalty Payments on account of sales or payments made by a licensee
or assignee of Capricor shall accrue and be payable to Medtronic by Capricor on a semiannual calendar basis within ninety (90)
days following the end of the applicable Royalty Period in which payment is received by Capricor from a licensee or assignee.

 

		I.	For each Royalty Period in which income derived from the Natriuretic Peptide Patents is received,
Capricor shall provide Medtronic with a written royalty statement in a form acceptable to Medtronic. Such royalty statement shall
be certified as accurate by a duly authorized officer of Capricor reciting, on a country-by-country basis, the reported Net Sales
for each Product sold during the Royalty Period for which income derived from the Natriuetic Peptide Patents is received. When
the Product(s) are sold for monies other than United States dollars, Royalty Payments will first be determined in the foreign currency
of the country in which the Sale was made and then converted into equivalent United States dollars. The exchange rate will be that
rate quoted in the Wall Street Journal on the last business day of the reporting period.

 

*Confidential Treatment
Requested

 

    	6

    	 

    

 

		J.	All payments due Medtronic shall be made in United States currency by check drawn on a U.S. bank.

 

		K.	Medtronic promotes public transparency in the relationships between industry and health care organizations/health
care professionals. To this end, Medtronic shall comply with all applicable federal and state laws including 42 U.S.C. Section
1320a-7h and all regulations and government guidance issued pursuant thereto (the “Transparency Requirements”). In
addition, on its public website, Medtronic discloses selected information attributable to U.S. physicians for certain services
and royalties. The current website address is available upon request. Capricor agrees that if Natriuretic Peptide Patents are transferred
to a physician or teaching hospital (as those terms are defined by the Transparency Requirements), Medtronic may be required to
disclose certain information relating to this Agreement, including payee’s name, name of health care professionals conducting
the activities for which compensation was paid hereunder, transfer of value amounts, the nature of transfers of value made by Medtronic,
and other information that may be required by the Transparency Requirements and Medtronic’s policies.

 

Article
5

NON-MONETARY SUPPORT

 

		A.	Capricor shall assume all costs and responsibility for the prosecution of all U.S. and foreign
patent applications for pending Natriuretic Peptide Patents incurred after the Effective Date of this Agreement.

 

		B.	If requested during the term of this Agreement, Medtronic shall provide up to 20 hours combined
per year of legal, technical and litigation support at a rate of $[...***...] per hour to Capricor to support Capricor’s
prosecution and maintenance of the Natriuretic Peptide Patents and/or to support enforcement of the Natriuretic Peptide Patents.
Medtronic does not warrant or assure the availability of any inventors or counsel that have contributed to the Natriuretic Peptide
Patents or take any liability related to providing the requested assistance. However, Medtronic will take reasonable steps to secure
the assistance of any inventors or counsel that have contributed to the Natriuretic Peptide Patents including the assistance of
inventors or counsel no longer employed by Medtronic.

 

		C.	Capricor will consider using the services of Dr. Worthley as a consultant or as a clinical investigator
during the development and clinical testing of any Natriuretic Peptide.

 

*Confidential Treatment
Requested

 

    	7

    	 

    

 

Article
6

DISCONTINUATION OF PROSECUTION

 

		A.	Capricor shall have sole discretion in prosecuting and maintaining the Natriuretic Peptide Patents.

 

		B.	Should Capricor decide to abandon any issued patent within the Natriuretic Peptide Patents by failing
to pay issue or maintenance fees, it shall provide written notice to Medtronic no less than ninety (90) days prior to any such
abandonment and Capricor shall assign such patent to Medtronic upon Medtronic’s request and at no cost to Medtronic; provided,
however, that nothing contained herein shall be construed to require Capricor to assign to Medtronic any of the rights it had in
any of the Natriuretic Peptide Patents existing prior to the Effective Date of this Agreement.

 

		C.	Should Capricor decide to cease prosecution of a patent family within the Natriuretic Peptide Patents
in a jurisdiction (regardless of whether patents within that family have issued in that jurisdiction) it shall provide written
notice to Medtronic no less than 90 days prior to any abandonment that would occur as a result, and Capricor shall assign the remaining
pending application(s) in such jurisdiction to Medtronic upon Medtronic’s request and at no cost to Medtronic. Capricor shall
receive a fully-paid up irrevocable non-exclusive license to any applications pending in the Natriuretic Peptide Patents that are
assigned back to Medtronic in pursuant to this Article 6.C to make, use or sell any Product developed by Capricor, with the right
to sublicense to a Non-Party Licensee, but only in connection with, and limited to, such Non-Party Licensee’s rights to commercialize
a natriuretic peptide-based Product and further provided that Capricor and Non-Party Licensee remains obligated to pay the royalty
and/or milestone payments provided in Article 4 with regard to such Product

 

		D.	Preservation of Medtronic’s Rights in Bankruptcy. If Capricor should file a petition under
bankruptcy laws, or if any involuntary petition shall be filed against Capricor, Medtronic shall be protected in the continued
enjoyment of its rights under this agreement to the maximum feasible extent including, if it so elects, the protection conferred
for intellectual property rights under Section 365 of Title 11 of the U.S. Code, or any similar provision of any applicable law.

 

		E.	Capricor represents and warrants to Medtronic that it will prosecute the Natriuretic Peptide Patents
in good faith and will not abandon any rights therein for a primary purpose of avoiding royalty or milestone payments under this
Agreement.

 

Article
7

RECORD INSPECTION AND AUDIT

 

During the term of this
Agreement and for a period of twelve (12) months thereafter, Medtronic shall have the right, upon reasonable notice, to inspect
Capricor’s financial books and records and all other documents and material in Capricor’s possession with respect to
the determination and payment of royalties and other financial obligations required under this Agreement. In no event shall Medtronic
have the right to examine information with respect to Capricor’s costs, pricing formulas, or percentages of markup. Capricor
shall impose similar obligations on any Non-Party Licensee for the benefit of itself and of Medtronic. For clarity, Medtronic shall
have no right to examine any other Confidential Information of Capricor or of any third party. The costs of any such audit shall
be borne by Medtronic and audits shall be limited to one time in each calendar year.

 

    	8

    	 

    

  

Article
8

WARRANTIES AND OBLIGATIONS

 

		A.	Medtronic represents and warrants that it holds full title to the Natriuretic Peptide Patents and,
except as to those co-owned by Capricor, no third party, including, without limitation, Madeleine Pharmaceuticals (“Madeleine”),
has any legal or equitable interest therein, including by license, assignment, or lien. For the purpose of clarity, Medtronic and
Madeleine jointly own the certain clinical studies performed and the data resulting therefrom under a prior agreement. Notwithstanding
the foregoing, Medtronic represents and warrants that such joint ownership does not impact or in any way affect Medtronic’s
sole and exclusive ownership of the Natriuretic Peptide Patents or its ability to make the assignment to Capricor as contemplated
herein.

 

		B.	Nothing in this Agreement shall be construed as any warranty or representation regarding the validity
or scope of any patent or Intellectual Property including the Natriuretic Peptide Patents.

 

		C.	Nothing in this Agreement shall be construed as any warranty or representation that anything made,
used, sold or otherwise disposed of under any transferred, assigned or licensed application for Letters Patent or issued Letters
Patent is free or will be free from infringement of any Intellectual Property rights of Non-Parties.

 

		D.	Medtronic hereby agrees not to sue Capricor or any Non-Party Licensee on account of any Product
sold during the term of this Agreement, which Product comprises a natriuretic peptide or a combination Product using a natriuretic
peptide and a delivery device, and shall not assert any claim that would block Capricor or a Non-Party Licensee’s commercialization
of such a Product during the term of this Agreement, provided that, in each case, the Product is read on by one or more claims
of the Natriuretic Peptide Patents. This covenant not to sue shall in no event extend to a supplier of a delivery device that would
infringe on other Medtronic device-specific patents.

 

		E.	Capricor covenants not to sue Medtronic under one or more claims of the Natriuretic Peptide Patents
on account of the sale of any medical device sold for use other than in combination with a Natriuretic Peptide; provided, however,
that nothing contained in this Section shall be construed to in any way to limit Capricor’s rights to enforce the Natriuretic
Peptide Patents against third parties.

 

    	9

    	 

    

  

		F.	Medtronic represents and warrants that there are no actions for infringement against Medtronic
nor has it received notice of or is it aware of infringement anywhere in the world with respect to items embodying the invention
of the Natriuretic Peptide Patents.

 

		G.	Nothing in this Agreement shall be construed as granting any Intellectual Property right by implication,
estoppel, or otherwise, or as licensing any rights other than the rights in the Natriuretic Peptide Patents.

 

Article
9

MARKING AND SAMPLES

 

Capricor shall and agrees
to require its Non-Party Licensees to fully comply with the patent marking provisions of the intellectual property laws of the
applicable countries in the Licensed Territory.

 

Article
10

INFRINGEMENTS

 

		A.	Capricor shall have the sole option and right, at its own cost and expense, to institute and prosecute
lawsuits for infringement of the Natriuretic Peptide Patents. The decision to institute, settle or terminate any action including
the terms thereof is solely at Capricor’s discretion as owner of the Natriuretic Peptide Patents.

 

		B.	Upon request of Capricor bringing a lawsuit, Medtronic shall execute all papers, testify on all
matters, and otherwise cooperate in every way necessary and desirable for the prosecution of any such lawsuit. Capricor shall reimburse
Medtronic for the expenses incurred as a result of such cooperation beyond the assistance provided for in Article 5, paragraph
B, of this Agreement, subject to the payment provisions of Article 4C.

 

Article
11

CONFIDENTIALITY

 

		A.	“Confidential Information” shall mean any confidential technical data, trade secret,
know-how or other confidential information disclosed by any party hereunder in writing, orally, or by drawing or other form and
which shall be marked by the disclosing party as “Confidential” or “Proprietary.” If such information is
disclosed orally, or through demonstration, the parties shall endeavor to designate it as being of a confidential nature at the
time of disclosure and reduced in writing and delivered to the receiving party within thirty (30) days of such disclosure. Notwithstanding
the foregoing, the failure to mark something confidential or reduce it to writing shall not cause such information to lose its
characterization of being confidential.

 

    	10

    	 

    

  

		B.	Notwithstanding the foregoing, Confidential Information shall not include information which: (i)
is known to the receiving party at the time of disclosure or becomes known to the receiving party without breach of this Agreement;
(ii) is or becomes publicly known through no wrongful act of the receiving party or any subsidiary of the receiving party; (iii)
is rightfully received from a third party without restriction on disclosure; (iv) is independently developed by the receiving party
or any of its subsidiaries; (v) is furnished to any third party by the disclosing party without restriction on its disclosure;
(vi) is approved for release upon a prior written consent of the disclosing party; (vii) is disclosed pursuant to judicial order,
requirement of a governmental agency or by operation of law.

 

		C.	The Parties covenant not to disclose the economic terms or conditions of this Agreement, other
than as required by law or regulation (including in SEC filings),or for the purpose of enforcing this Agreement in a court of law,
without prior written approval from the other Party. In addition Capricor shall have the right to disclose the terms and conditions
of this Agreement to its business consultants, advisors and business prospects so long as such persons or entities are under obligations
of confidentiality with Capricor. Notwithstanding the foregoing, the Parties will agree upon and permit Capricor to release a press
release to announce the execution of this Agreement, which is attached hereto as Schedule B, and which may be used in responding
to inquiries about this Agreement. Thereafter, the Parties may each disclose to third parties the information contained in such
press release without the need for further approval by the other, provided that such information is still accurate.

 

		D.	If a Party breaches any of its obligations with respect to confidentiality and unauthorized use
of Confidential Information hereunder, the non-breaching party shall be entitled to equitable relief to protect its interest therein,
including but not limited to injunctive relief, as well as money damages notwithstanding anything to the contrary contained herein.

 

Article
12

EXPORT CONTROL

 

Anything contained in this
Agreement to the contrary notwithstanding, the obligations of the Parties hereto and of the Affiliates of the Parties shall be
subject to all laws, present and future and including export control laws and regulations, of any government having jurisdiction
over the Parties hereto or the Affiliates of the Parties, and to orders, regulations, directions or requests of any such government.
Each Party shall undertake to comply with and be solely responsible for complying with such laws applicable to such Party.

 

Article
13

TAXES AND GOVERNMENTAL APPROVALS

 

		A.	Capricor shall be solely responsible for the payment of any and all taxes, fees, duties and other
payments incurred in relation to the manufacture, use and sale of Product(s).

 

		B.	Capricor shall be solely responsible for applying for and obtaining any approvals, authorizations,
or validations necessary to sell any Product(s) under the laws of the appropriate national laws of each of the countries where
such Product(s) may be sold.

 

    	11

    	 

    

  

Article
14

FORCE MAJEURE

 

Neither Party will be liable
for or will be considered to be in breach of or default under this Agreement on account of any delay or failure to perform as required
by this Agreement as a result of any causes or conditions that are beyond such Party’s reasonable control and that such Party
is unable to overcome through the exercise of commercially reasonable diligence. If any force majeure event occurs, the affected
Party will give prompt written notice to the other Party and will use commercially reasonable efforts to minimize the impact of
the event.

 

Article
15

NOTICE AND PAYMENT

 

		A.	Any notice required to be given under this Agreement shall be in writing and delivered personally
to the other designated party at the below stated addresses or mailed by certified, registered or Express mail, return receipt
requested or by FedEx.

 

	If to Medtronic:	If to Capricor:
	 	 
	Medtronic Patent Department	Capricor Therapeutics, Inc.
	Medtronic, Inc.	8840 Wilshire Blvd., 2nd Floor
	710 Medtronic Parkway	Beverly Hills, CA 90211
	Minneapolis, MN 55432-5604 USA	ATTN:  Karen G. Krasney, General Counsel
	Attn.:  Ken Collier, Principal Counsel	 

 

		B.	Either Party may change the address to which notice or payment is to be sent by written notice
to the other under any provision of this Article.

 

Article
16

GOVERNING LAW

 

This Agreement shall be
governed in accordance with the laws of the State of Delaware except that any ethical obligations of counsel for Capricor are governed
solely by the laws of the California.

 

Article
17

AGREEMENT BINDING ON SUCCESSORS

 

The provisions of the Agreement
shall be binding upon and shall inure to the benefit of the Parties hereto, their heirs, administrators, successors and assigns.

 

    	12

    	 

    

  

Article
18

WAIVER

 

No waiver by either party
of any default shall be deemed as a waiver of prior or subsequent default of the same of other provisions of this Agreement.

 

Article
19

SEVERABILITY

 

If any term, clause or
provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity
or operation of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed from
the Agreement.

 

Article
20

INTEGRATION

 

Except as otherwise stated
herein, this Agreement constitutes the entire understanding of the Parties, and revokes and supersedes all prior agreements between
the Parties and is intended as a final expression of their Agreement. It shall not be modified or amended except in writing signed
by the Parties hereto and specifically referring to this Agreement. This Agreement shall take precedence over any other documents
which may conflict with this Agreement. Notwithstanding the foregoing, the Clinical Funding Agreement previously executed by the
Parties shall not be superseded by this Agreement except to the extent it expressly conflicts with the terms contained herein (e.g.
Royalty Payment due on Net Sales of Products).

 

IN WITNESS WHEREOF, the
Parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the day
indicated.

 

	MEDTRONIC, INC.	 	CAPRICOR THERAPEUTICS, INC.
	 	 	 	 	 
	By:	/s/ Christopher M. Cleary	 	By:	/s/ Linda Marbán
	 	 	 	 	 
	Name:	Christopher M. Cleary	 	Name:	Linda Marbán
	 	 	 	 	 
	Title:	Vice President, Corporate Development	 	Title:	Chief Executive Officer
	 	 	 	 	 
	Date:	October 8, 2014	 	Date:	October 8, 2014

 

    	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]